Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • It’s raining contracts for Fluence, with $4m of new wins for water works
    • News

    It’s raining contracts for Fluence, with $4m of new wins for water works

    Global wastewater solutions company Fluence (ASX: FLC) has pulled a “new (financial) year, new us” move as it secures new contracts and realigns the company to boost efficiency. The Company has secured new strategic orders, including its first wastewater treatment contracts in Taiwan and Korea. Plus, the Company is undertaking organisational improvements to boost its

    Read More
    Public
  • Best & Less online sales down 33%, counts on the holiday season to bring numbers up
    • News

    Best & Less online sales down 33%, counts on the holiday season to bring numbers up

    Even as prices soar in everyday stores, Aussie mums are not about to strike a compromise. When buying clothes for their kids, they want the best, even if that means spending more. Perhaps that’s why, even when online shopping is all the rage, retail company Best & Less (ASX: BST) is witnessing its online sales

    Read More
    Public
  • Invex randomises the first patient for phase III trial of its IIH drug
    • News

    Invex randomises the first patient for phase III trial of its IIH drug

    Imagine a headache so intense that the literal ear-throbbing pain results in blindness or other vision impairments. Even though sometimes it may not be so extreme, Idiopathic Intracranial Hypertension (IIH) can take such a form, making it integral to develop a cure for the same. Invex (ASX: IXC) believes that it has got one with

    Read More
    Public
  • Little Green Pharma winds down German distribution deal
    • News

    Little Green Pharma winds down German distribution deal

    A key player in the global cannabis market, Little Green Pharma (ASX: LGP), has pulled the plug on its German distributor, Four 20 Pharma GmbH, after failing to meet the contract terms to bring a highly-prospective new THC strain to the German medical cannabis market by 19th November 2022. Licensed as a manufacturer, wholesaler, and

    Read More
    Public
  • Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company
    • News

    Zelira enrols sixty patients for diabetic nerve pain drug trial as it attempts to overthrow major pharma company

    Biopharmaceuticals company Zelira (ASX: ZLD) is taking a stab at redemption. After a misstep this July by not announcing its German expansion, the Company lost shareholder trust. Now, it is attempting to get it back with new milestones revealed on time for its clinical trials targeting diabetic nerve pain.  The trial has been designed as

    Read More
    Public
  • Cettire founder cashes out another $41 million as shares dive on sell-down
    • News

    Cettire founder cashes out another $41 million as shares dive on sell-down

    A CEO is the ultimate “inside man” of a company, no one knows the business better than they do. However, when they have started to sell a huge chunk of their shares every few months, is there a clearer telltale sign that the company has fallen from grace? Luxury goods retailer Cettire (ASX: CTT) confirmed

    Read More
    Public
  • «
  • ‹
  • 309
  • 310
  • 311
  • 312
  • 313
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.